Trinomab was jointly founded by the worldwide known expert Dr. Liao Huaxin and the entrepreneur Mr. Zheng Weihong. Its core technology is the fourth-generation antibody technology platform HitmAb, which is dedicated to the development of original and efficient natural fully human mAbs with independent intellectual property rights, suitable for infectious diseases, autoimmune diseases and malignant tumors, etc. The best feature of the natural fully human mAb developed by HitmAb is its high safety, having broad spectrum to foreign pathogens and strong affinity with pathogen targets, which can solve the problem of anti-drug antibody (ADA) reaction in the clinical use of antibody drugs developed by traditional technologies. Based on the HitmAb platform, Trinomab has developed more than 20 new native human mAbs, including those against infectious diseases and cancers, among which, certain antibodies are in the process of rapid industrialization.
Fully Human Anti-SA Hlα Antibody can neutralize the Hlα released by SA to avoid Immune downregulation to B cells and to improve immune response. Hlα toxin is the most widely expressed one among toxins SA produced, but currently there is no Hlα antibody drug launched in the world. The product has good safety and its preclinical studies have shown good Hlα toxin neutralizing activity. It is expected to solve the problems of high mortality, resistance to treatment, and side effects from SA infection.
Fully Human Anti-HCMV Antibody can neutralize free virus in blood and has the capacity for neutralization within cells twice. Currently, there is no HCMV vaccine launched in the world. The product has a precise mechanism of action and excellent safety, and can be produced on a large scale under strict quality control due to its non-blood-derived production process. It is expected to fill the gap of HCMV monoclonal antibodies in the world.
Fully Human Anti-rabies Virus Antibody can confer passive immune response to rabies virus through providing required neutralizing antibodies at the site of exposure within 0-7 days after exposure, when the body is not able to generate its own antibodies induced by active immunization with vaccine. The marketed passive immunization agents in China are subject to production capacity limitation due to the blood plasma-derived production process, and their market penetration rate is relatively low. As a non-blood plasma-derived product, Fully Human Anti-rabies Virus Antibody may become a passive immunization medicine for rabies virus that is not limited by related production capacity issues, while having high safety and strong affinity.
Fully Human Anti-COVID-19 Antibody is a neutralizing antibody cocktail, and can provide broad neutralizing activities and cover a wider population. It has good safety, specificity and high affinity, and its preclinical data shows that it is effective against major current strains, including the South African and Indian variants. Facing the potential pandemic caused by these variants, the product is expected to further meet the global needs for prevention and treatment of COVID-19 infection.